Citations

Clear

2303 citation(s) found for "Yu, Edward".

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Spratt, Daniel E. , Alshalalfa, Mohammed , Fishbane, Nick , Weiner, Adam B. , Mehra, Rohit , Mahal, Brandon A. , Lehrer, Jonathan , Zhao, Shuang G. , Speers, Corey , Morgan, Todd M. , Dicker, Adam P. , Freedland, Stephen J. , Karnes, R. Jeffery, Weinmann, Sheila , Ross, Ashley E. , Nguyen, Paul L. , Feng, Felix Y. , Chinnaiyan, Arul M., Schaeffer, Edward M. , Speers, Corey , Davicioni, Elai , Den, Robert B , Spratt, Daniel E , Morgan, Todd M , Dicker, Adam P , Liu, Yang , Zhao, Shuang G , Karnes, R. Jeffrey , Davicioni, Elai , Den, Robert B. , Lotan, Tamara Levin

Mayo Clinic

Clinical Cancer Research | September 12, 2019 | Volume: 25 | Issue: 22 | Pages: 6721-6730

10.1158/1078-0432.ccr-19-1587 | PMID 31515456 Get It

Abstract Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications of AR-A in treatment-naïve primary prostate cancer is largely unknown. We sought to characterize AR-A in localized prostate cancer and understand its molecular and clinical implications. Experimental Design: Genome-wide expression profiles from prostatectomy or biopsy samples from 19,470 patients were used, all with independent pathology review. This was comprised of prospective discovery (n = 5,239) and validation (n = 12,728) cohorts, six retrospective institutional cohorts with long-term clinical outcomes data (n = 1,170), and The Cancer Genome Atlas (n = 333). Results: A low AR-active subclass was identified, which comprised 9%–11% of each cohort, and was characterized by increased immune signaling, neuroendocrine expression, and decreased DNA repair. These tumors were predominantly ERG and basal subtype. Low AR-active tumors had significantly more rapid development of recurrence or metastatic disease across cohorts, which was maintained on multivariable analysis [HR, 2.61; 95% confidence interval (CI), 1.22–5.60; P = 0.014]. Low AR-active tumors were predicted to be more sensitive to PARP inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy. This was validated clinically, in that low AR-active tumors were less sensitive to androgen-deprivation therapy (OR, 0.41; 95% CI, 0.21–0.80; P = 0.008). Conclusions: Leveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a preexisting subgroup of patients may have tumors that are predisposed to fail multiple current standard-of-care therapies and warrant dedicated therapeutic investigation.
Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging
Adler, Charles H. , Beach, Thomas G. , Shill, Holly A. , Driver‐Dunckley, Erika , Caviness, John N., Mehta, Shyamal H. , Sue, Lucia I., Belden, Christine M. , Powell, Jessica, Jacobson, Sandra A. , Zamrini, Edward , Shprecher, David , Davis, Kathryn, Dugger, Brittany N. , Hentz, Joseph G. , Driver-Dunckley, Erika, Adler, C H , Shprecher, David , Dugger, Brittany N , Zhang, Nan , Sabbagh, Marwan Noel , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 10, 2019 | Volume: 78 | Issue: 10 | Pages: 891-899

10.1093/jnen/nlz080 | PMID 31504679 Get It

Abstract This study was designed to correlate clinical findings with the extent of pathologic a-synuclein (aSyn) in the brain using the Unified Staging System for Lewy Body disorders (USSLB). Data from 280 cases from the Arizona Study of Aging and Neurodegenerative Disorders are presented. Each case had a complete USSLB staging and at least 1 full research clinical assessment, including subspecialty neurologist-administered movement and cognitive evaluation. Of the 280, 25.7% were cognitively normal, 8.6% had mild cognitive impairment, and 65.7% had dementia. All cases could be categorized into 1 of 5 USSLB stages (8.6% stage I—olfactory bulb only; 15.4% IIa—brainstem predominant; 13.6% IIb—limbic predominant; 31.8% III—brainstem and limbic; and 30.7% IV—neocortical) yet using the Braak staging system 70 cases (25.3%) could not be classified. Those with USSLB stages III and IV died at a younger age. Multiple measures of motor parkinsonism, cognitive impairment, hyposmia, and probable RBD were significantly correlated with increasing USSLB stage. We conclude that the USSLB is the most comprehensive staging system for all Lewy body disorders and allows for categorization and ranking of all brains with significant correlations to many motor and nonmotor clinical signs and symptoms.
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
Crow, Lauren , Jambusaria‐Pahlajani, Anokhi , Chung, Christina Lee , Baran, David A. , Lowenstein, Stefan E. , Abdelmalek, Mark, Ahmed, Rehana L. , Anadkat, Milan J. , Arcasoy, Selim M. , Berg, Daniel , Bibee, Kristin , Billingsley, Elizabeth M. , Black, William H., Blalock, Travis W. , Bleicher, Melissa, Brennan, Daniel C. , Brodland, David G., Brown, Mariah , Carroll, Bryan T. , Carucci, John A. , Chang, Timothy W., Chaux, George, Cusack, Carrie Ann, Dilling, Daniel F. , Doyle, Alden , Emtiazjoo, Amir , Ferguson, Nkanyezi H., Fosko, Scott W. , Fox, Matthew C., Göral, Simin , Gray, Alice , Griffin, John R., Hall, Shelley , Hanlon, Allison , Hayes, Don , Hickey, Gavin , Holtz, Jonathan E., Hopkins, R. Samuel, Hu, Jenny, Huang, Conway C. , Kapnadak, Siddhartha G. , Kraus, Edward S., Leitenberger, Justin J. , Lim, Mary Ann , Longo, María Isabel , Malik, Shahid M. , Menter, Alan , Myers, Sarah A., Neuburg, Marcy, Nijhawan, Rajiv I. , Norman, Douglas J., Otley, Clark C. , Paek, So Yeon , Parulekar, Amit , Patel, Manisha J., Patton, Timothy , Pugliano‐Mauro, Melissa , Ranganna, Karthik, Redenius, Rachel, Samie, Faramarz H. , Shin, Thuzar M. , Singer, Jonathan P. , Singh, Pooja , Soon, Seaver L. , Squires, Ronald A., Stasko, Thomas, Stein, Jennifer , Taler, Sandra J. , Thomas, Christie P. , Tokman, Sofya , Tomic, Rade , Twigg, Amanda R. , Wigger, M., Zeitouni, Nathalie C., Crow, Lauren D , Leca, Nicolae , Mallea, Jorge M. , Tomic, Rade , Singer, Jonathan P , Baran, David A , Paek, So Yeon , Ferguson, Nkanyezi , Hachem, Ramsey R. , Jiang, Shang I. Brian , Lease, Erika D. , Lee, James , Patel, Vishal Anil , Ravichandran, Ashwin Kumar , Redenius, Rachel A., Roll, Garrett Richard , Soriano, Teresa T. , Terrault, Norah A. , Arron, Sarah T. , Thomas, Christie P

Mayo Clinic

Transplant International | September 10, 2019 | Volume: 32 | Issue: 12 | Pages: 1268-1276

10.1111/tri.13520 | PMID 31502728 Get It

Pseudomonas Aeruginosa Associated with Severity of Non-Cystic Fibrosis Bronchiectasis Measured by the Modified Bronchiectasis Severity Score (BSI) and the FACED: The US Bronchiectasis and NTM Research Registry (BRR) Study
Aksamit, Timothy R. , Stone, Glenda , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Choate, Radmila , Mannino, David M. , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Salathe, Matthias A. , Schmid, Andreas Alexander

Mayo Clinic

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5716-A5716

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5716 Get It

Airway Clearance in Non-Cystic Fibrosis Bronchiectasis: Analysis from the United States Bronchiectasis Research Registry
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Turino, Gerard M., Winthrop, Kevin , O'Donnell, Anne E , Basavaraj, Ashwin , Choate, Radmila , Addrizzo‐Harris, Doreen , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5700-A5700

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5700 Get It

Impact of a Multidisciplinary eBoard on the Management of Patients With Complex Inflammatory Bowel Disease
Quinn, Kevin P. , Prothero, Breanne, Russell, Jennifer M. , Hegge, Ryan, Bormann, Alexander G. von, Larson, Putchalee, Christofferson, Sara, Smyrk, Thomas C. , Mathis, Kellie L. , Goenka, Ajit H. , Sheedy, Shannon P. , Bruining, David H. , Loftus, Edward V. , Raffals, Laura E. , Loftus, Edward V , Fletcher, Joel G.

Mayo Clinic

Crohn's & Colitis 360 | August 20, 2019 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/crocol/otz013 Get It

Abstract Background We aim to assess the impact of a multidisciplinary inflammatory bowel disease (IBD) conference on the management of patients with complex IBD. Methods Data were collected during each conference from February 2017 through October 2018 with chart review performed at 6 months to determine if conference recommendations were successfully implemented. Results Eighty-five patients were discussed. The presenting diagnosis was changed by 11.8%. Recommendations for further testing, medical therapy, and surgery were successfully implemented in 77.1%, 98.1%, and 88.4%, respectively. Conclusions This study supports the role of IBD multidisciplinary conferences in the management of patients with complex IBD.
Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn’s Disease: Single-Center Series
Alsughayer, Ahmad, Petersen, M. , Raffals, Laura E. , Loftus, Edward V. , Loftus, Edward V , Lightner, Amy L. , Grass, Fabian

Mayo Clinic

Crohn's & Colitis 360 | August 16, 2019 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/crocol/otz018 Get It

Abstract Introduction The impact of ustekinumab on adverse postoperative outcomes in Crohn’s disease (CD) remains largely unknown. We determined the difference in 90-day postoperative complication rates among CD patients exposed to ustekinumab within 12 weeks prior to an abdominal operation as compared to patients not exposed to biologic therapy. Methods A retrospective chart review of all adults with CD who underwent an abdominal operation between October 1, 2017 and December 31, 2018 at a single tertiary medical center was performed. Data collection included patient demographics, concurrent immunosuppression, serum laboratory values, operative values, and 90-day outcomes including superficial surgical site infection (sSSI), intra-abdominal sepsis, overall infectious complications, readmission, and reoperation rates. The primary outcome was the 90-day rate of intra-abdominal sepsis. Results Fifty-seven CD patients received ustekinumab and 277 received no biologic therapy in the 12 weeks prior to major abdominal surgery. Ustekinumab-exposed patients were younger, less likely to have diabetes mellitus or active tobacco exposure, were more often obese, and more often taking a concurrent immunomodulator. Ustekinumab remained an independent predictor of intra-abdominal sepsis on multivariable logistic regression. Immunomodulator exposure was associated with significantly increased rates of sSSI and overall complication rates. Conclusions Ustekinumab is associated with increased rates of 90-day postoperative intra-abdominal sepsis following a major abdominal operation for CD.
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Sato, Kaori , Ng, Kimmie , Blarigan, Erin Van, Blanke, Charles D. , O’Reilly, Eileen M. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Niedzwiecki, Donna , Ou, Fang‐Shu , Venook, Alan P. , Shaw, James Edward , Blarigan, Erin L. Van , Mayer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | August 13, 2019 | Volume: 37 | Issue: 29 | Pages: 2620-2631

10.1200/jco.19.01019 | PMID 31408415 Get It

PURPOSERegular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored.PATIENTS AND METHODSWe conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850 ), a National Cancer Institute–sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss.RESULTSThe final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend= .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend= .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend< .001).CONCLUSIONAmong patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.
Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy
Neumann, Hartmut P.H., Tsoy, Uliana, Amodru, Vincent , Walz, Martin K. , Kaur, Ravinder Jeet , McKenzie, Travis J. , Qi, Xiao-Ping , Bandgar, Tushar , Petrov, Roman , Yukina, M. Yu. , Roslyakova, Anna , Horst‐Schrivers, Anouk N.A. van der , Berends, Annika M.A. , Hoff, Ana O. , Castroneves, Luciana Audi , Rizzati, Silvia, Mian, Caterina , Dvořáková, Šárka , Hasse-Lazar, Kornelia , Kvachenyuk, Andrey, Pęczkowska, Mariola , Loli, Paola , Erenler, Feyza , Krauß, Tobias , Almeida, Madson Q. , Liu, Longfei , Zhu, Feizhou , Recasens, Mònica, Wohllk, Nelson , Corssmit, Eleonora P.M. , Kunavisarut, Tada , Schalin‐Jäntti, Camilla , Castinetti, Frédéric , Vlček, Petr , Beltsevich, D. G. , Егоров, В. И. , Schiavi, Francesca , Links, Thera P. , Lechan, Ronald M. , Bausch, Birke, Group, for the International Bilateral-Pheochromocytoma-Registry, Ngeow, Joanne , Jarząb, Barbara , Hudiakova, N. V. , Fragoso, Maria Candida Barisson Villares , Grineva, Elena , Tsoy, U. A. , Opocher, Giuseppe , Ngeow, Joanne , Bancos, Irina , Tirosh, Amit , Ferrara, Alfonso Massimiliano , Recasens, Monica, Shafigullina, Zulfiya R. , Calissendorff, Jan , Grozinsky‐Glasberg, Simona , Egorov, Viacheslav I., Young, William F. , Eng, Charis , Almeida, Madson Q

Mayo Clinic

JAMA Network Open | August 9, 2019 | Volume: 2 | Issue: 8 | Pages: e198898

10.1001/jamanetworkopen.2019.8898 | PMID 31397861 Get It

Outcome of endoscopic resection of colonic polyps larger than 10 mm in patients with inflammatory bowel disease
Yadav, Siddhant, Harmsen, William S. , Song, Louis M. Wong Kee , Wong Kee Song, Louis M, Loftus, Edward V. , Coelho–Prabhu, Nayantara

Mayo Clinic

Endoscopy International Open | August 8, 2019 | Volume: 07 | Issue: 08 | Pages: E994-E1001

10.1055/a-0953-2021 | PMID 31404424 Get It

Abstract Background and study aims There are limited published data on endoscopic removal of colorectal polyps by endoscopic mucosal resection (EMR) and endoscopic mucosal dissection (ESD) in patients with inflammatory bowel disease (IBD). Patients and methods We performed a retrospective review of patients with colonic IBD and colonic polyps >10mm who underwent EMR and/or ESD at our institution between January 1, 2012 and June 31, 2016. Results Ninety-seven patients with pathology-confirmed IBD (median disease duration 16 years) were included. Mild or moderate active colitis (in background biopsies) was seen in 85 %. Of the total 124 polyps, location was ascending colon in 44 %, transverse in 15 % and sigmoid in 18.5 %; of the total, 55 % were < 20 mm and 45 % were ≥20mm in maximal diameter. Using the Paris classification, 56 % of polyps were polypoid sessile (Is) polyps, while 38 % were non-polypoid (IIa, IIb, IIc). EMR was used in 118 polyps, three required ESD, and three by combined EMR-ESD. Seventy-two percent were resected en-bloc; 28 % underwent piecemeal resection. Histology included low-grade dysplasia in 75, serrated adenoma in 31, and tubular adenoma in 14 polyps. Chromoendoscopy was used in 33 (26.6 %). Adverse events occurred in three patients. Colectomy was performed in 11 patients within 12 months. Recurrence was seen in 20 polyps, 11 of which were successfully resected en-bloc using EMR. Polyps ≥ 20 mm and polyps treated with APC were found to have a statistically significantly higher risk of recurrence. Conclusion This study demonstrates the efficacy and safety of endoscopic resection of large polyps in patients with IBD, making them effective alternatives to colectomy.